By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ)

SHZ Currency in CNY
¥18.67
+¥0.11
+0.59%
Last Update: 17 Jul 2025, 07:04
¥12.82B
Market Cap
21.71
P/E Ratio (TTM)
Forward Dividend Yield
¥11.53 - ¥19.36
52 Week Range

300181.SZ Stock Price Chart

Explore Zhejiang Jolly Pharmaceutical Co.,LTD interactive price chart. Choose custom timeframes to analyze 300181.SZ price movements and trends.

There is nothing to show.

300181.SZ Company Profile

Discover essential business fundamentals and corporate details for Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

22 Feb 2011

Employees

2.69K

CEO

Tao Wang

Description

Zhejiang Jolly Pharmaceutical Co., Ltd. engages in the research, production, and marketing of Chinese medicinal products in China and internationally. The company offers Wuling capsule that is used to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney. In addition, the company offers Linglianhua particles for the treatment of symptoms, including sweating, insomnia, dysphoria, heart palpitations, dreaminess, giddy tinnitus, lassitude in loin and legs, dry stool, and abnormal furred tongue, as well as weak pulse caused by perimenopausal syndrome, or disharmony of heart and kidney. Further, it provides azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside injections. Additionally, the company offers materials, such as cordyceps cephalosporium, fermented cordyceps, and Wuling powders. It also invests and participates in the medical services of Deqing No.3 People's Hospital. The company was formerly known as Zhejiang Jolly Pharmaceutical Health Products Co., LTD. and changed its name to Zhejiang Jolly Pharmaceutical Co., Ltd. in 1998. Zhejiang Jolly Pharmaceutical Co., Ltd. was founded in 2000 and is based in Huzhou, China.

300181.SZ Financial Timeline

Browse a chronological timeline of Zhejiang Jolly Pharmaceutical Co.,LTD corporate events including earnings releases, dividend announcements, and stock splits.

Earnings released on 24 Apr 2025

EPS came in at ¥0.26, while revenue for the quarter reached ¥824.43M.

Earnings released on 9 Mar 2025

EPS came in at ¥0.12, while revenue for the quarter reached ¥533.00M.

Earnings released on 27 Oct 2024

EPS came in at ¥0.18, while revenue for the quarter reached ¥616.62M.

Earnings released on 29 Jul 2024

EPS came in at ¥0.22, while revenue for the quarter reached ¥744.29M.

Dividend declared on 22 May 2024

A dividend of ¥0.45 per share was announced, adjusted to ¥0.45. The dividend was paid on 22 May 2024.

Earnings released on 18 Apr 2024

EPS came in at ¥0.20, while revenue for the quarter reached ¥672.90M.

Earnings released on 11 Mar 2024

EPS came in at ¥0.14, while revenue for the quarter reached ¥477.55M.

Earnings released on 22 Oct 2023

EPS came in at ¥0.13, while revenue for the quarter reached ¥453.49M.

Earnings released on 9 Aug 2023

EPS came in at ¥0.14, while revenue for the quarter reached ¥515.76M.

Dividend declared on 30 May 2023

A dividend of ¥0.30 per share was announced, adjusted to ¥0.30. The dividend was paid on 30 May 2023.

Earnings released on 25 Apr 2023

EPS came in at ¥0.14, while revenue for the quarter reached ¥495.70M.

Earnings released on 14 Mar 2023

EPS came in at ¥0.11, while revenue for the quarter reached ¥460.75M.

Earnings released on 25 Oct 2022

EPS came in at ¥0.11, while revenue for the quarter reached ¥449.45M.

Earnings released on 30 Aug 2022

EPS came in at ¥0.11, while revenue for the quarter reached ¥455.53M.

Dividend declared on 31 May 2022

A dividend of ¥0.20 per share was announced, adjusted to ¥0.20. The dividend was paid on 31 May 2022.

Earnings released on 20 Apr 2022

EPS came in at ¥0.11, while revenue for the quarter reached ¥439.42M.

Earnings released on 10 Mar 2022

EPS came in at ¥0.08, while revenue for the quarter reached ¥378.93M.

Earnings released on 26 Oct 2021

EPS came in at ¥0.07, while revenue for the quarter reached ¥380.80M.

Earnings released on 28 Jul 2021

EPS came in at ¥0.07, while revenue for the quarter reached ¥357.52M.

Dividend declared on 31 May 2021

A dividend of ¥0.10 per share was announced, adjusted to ¥0.10. The dividend was paid on 31 May 2021.

Earnings released on 27 Apr 2021

EPS came in at ¥0.07, while revenue for the quarter reached ¥340.16M, missing expectations by -86.58%.

Earnings released on 10 Mar 2021

EPS came in at ¥0.04, while revenue for the quarter reached ¥321.33M.

Earnings released on 30 Oct 2020

EPS came in at ¥0.05, while revenue for the quarter reached ¥302.76M.

Earnings released on 31 Jul 2020

EPS came in at ¥0.03, while revenue for the quarter reached ¥273.60M.

300181.SZ Stock Performance

Access detailed 300181.SZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

There is nothing to show.
300181.SZ
Company Name
Exchange
Market Currency
Report Currency
Price
Price Change
Percentage Change
50-Day Average Price
200-Day Average Price
Trading Volume
Market Capitalization
300181.SZ
2025
2024
2023
2022
2021
Revenue
Gross Profit
Earnings Before Interest and Taxes (EBIT)
Net Income
Total Current Assets
Total Assets
Total Liabilities
Net Debt
Total Equity
Cash Flow from Operating
Cash Flow from Investing
Cash Flow from Financing
Free Cash Flow

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More